A new series of estrogen receptor modulators that display selectivity for estrogen receptor β

Journal of Medicinal Chemistry

Volumn 45, Issue 25, 2002, Pages 5492-5505

  Henke, Brad R ^a   Consler, Thomas G ^a   Go, Ning ^b   Hale, Ron L ^b,c   Hohman, Dana R ^b,d   Jones, Stacey A ^a   Lu, Amy T ^b,c   Moore, Linda B ^a   Moore, John T ^a   Orband Miller, Lisa A ^a   Robinett, R Graham ^a   Shearin, Jean ^a   Spearing, Paul K ^a   Stewart, Eugene L ^a   Turnbull, Philip S ^a   Weaver, Susan L ^a   Williams, Shawn P ^a   Wisely, G Bruce ^a   Lambert, Millard H ^a  

^a GLAXOSMITHKLINE   (United States)

^b AFFYMAX RESEARCH INSTITUTE   (United States)

^c Alexza Pharmaceuticals   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; RECEPTOR SUBTYPE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRIAZINE DERIVATIVE;

ARTICLE; BINDING AFFINITY; BINDING ASSAY; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; IN VITRO STUDY; LIGAND BINDING; REPORTER GENE; SCREENING; STRUCTURE ACTIVITY RELATION;

CRYSTALLOGRAPHY, X-RAY; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENES, REPORTER; HUMANS; LIGANDS; MODELS, MOLECULAR; RADIOLIGAND ASSAY; RECEPTORS, ESTROGEN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION, GENETIC; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 0037028042     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020291h     Document Type: Article

References (53)

1. Cosman, F.; Lindsay, R. Selective estrogen receptor modulators: Clinical spectrum. Endocr. Rev. 1999, 20, 418-434.
2. Barrett-Connor, E.; Cox, D. A.; Anderson, P. W. The Potential of SERMs for Reducing the Risk of Coronary Heart Disease. Trends Endocrinol. Metab. 1999, 10, 320-325.
3. Yaffe, K.; Sawaya, G.; Lieberburg, I.; Grady, D. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia. JAMA, J. Am. Med. Assoc. 1998, 279, 688-695.
4. Zumoff, B. Does postmenopausal estrogen administration increase the risk of breast cancer? Contributions of animal, biochemical, and clinical investigative studies to a resolution of the controversy. Proc. Soc. Exp. Biol. Med. 1998, 217, 30-37.
5. Beresford, S. A.; Weiss, N. S.; Voigt, L. F.; McKnight, B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997, 349, 458-461.
6. Grese, T. A.; Dodge, J. A. Selective estrogen receptor modulators (SERMs). Curr. Pharm. Des. 1998, 4, 71-92.
7. Lin, X.; Huebner, V. Non-steroidal ligands for steroid hormone receptors. Curr. Opin. Drug Discovery Dev. 2000, 3, 383-398.
8. McDonnell, D. P. The molecular pharmacology of SERMs. Trends Endocrinol. Metab. 1999, 10, 301-311.
9. Kuiper, G. G. J. M.; Enmark, E.; Pelto-Huikko, M.; Nilsson, S.; Gustafsson, J.-A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 5925-5930.
10. Mosselman, S.; Polman, J.; Dijkema, R. ERβ: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996, 392, 49-53.
11. Kuiper, G. G. J. M.; Gustafsson, J.-A. The novel estrogen receptor-β subtype: Potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett. 1997, 410, 87-90.
12. Kuiper, G. G. J. M.; Carlsson, B.; Grandien, K.; Enmark, E.; Haeggblad, J.; et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 1997, 138, 863-870.
13. Hewitt, S. C.; Couse, J. F.; Korach, K. S. Estrogen receptor transcription and transactivation. Estrogen receptor knockout mice: What their phenotypes reveal about mechanisms of estrogen action. Breast Cancer Res. 2000, 2, 345-352.
14. Couse, J. F.; Korach, K. S. Estrogen receptor null mice: What have we learned and where will they lead us? Endocr. Rev. 1999, 20, 358-417.
15. Dupont, S.; Krust, A.; Gansmuller, A.; Dierich, A.; Chambon, P.; et al. Effect of single and compound knockouts of estrogen receptors α (ERα) and β (ERβ) on mouse reproductive phenotypes. Development 2000, 127, 4277-4291.
16. Barkhem, T.; Carlsson, B.; Nilsson, Y.; Enmark, E.; Gustafsson, J.-A.; et al. Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. Mol. Pharmacol. 1998, 54, 105-112.
17. Meyers, M. J.; Sun, J.; Carlson, K. E.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Estrogen receptor subtype-selective ligands: Asymmetric synthesis and biological evaluation of cis- and trans-5,11-dialkyl-5,6,11,12-tetrahydrochrysenes. J. Med. Chem. 1999, 42, 2456-2468.
18. Stauffer, S. R.; Coletta, C. J.; Tedesco, R.; Nishiguchi, G.; Carlson, K.; et al. Pyrazole ligands: Structure-affinity/activity relationships and estrogen receptor-α selective agonists. J. Med. Chem., 2000, 43, 4934-4947.
19. Stauffer, S. R.; Sun, J.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Acyclic amides as estrogen receptor ligands: Synthesis, binding, activity and receptor interaction. Bioorg. Med. Chem. 2000, 8, 1293-1316.
20. Sun, J.; Meyers, M. J.; Fink, B. E.; Rajendran, R.; Katzenellenbogen, J. A.; et al. Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-α or estrogen receptor-β. Endocrinology 1999, 140, 800-804.
21. Schopfer, U.; Schoeffter, P.; Bischoff, S. F.; Nozulak, J.; Feuerbach, D.; et al. Toward selective ERβ agonists for central nervous system disorders: Synthesis and characterization of aryl benzthiophenes. J. Med. Chem. 2002, 45, 1399-1401.
22. Meyers, M. J.; Sun, J.; Carlson, K. E.; Marriner, G. A.; Katzenellenbogen, B. S.; et al. Estrogen receptor-β potency-selective ligands: Structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J. Med. Chem. 2001, 44, 4230-4251.
23. Masquelin, T.; Meunier, N.; Gerber, F.; Rosse, G. Solution- and solid-phase synthesis of combinatorial libraries of trisubstituted 1,3,5-triazines. Heterocycles 1998, 48, 2489-2505.
24. Scharn, D.; Wenschuh, H.; Reineke, U.; Schneider-Mergener, J.; Germeroth, L. Spatially addressed synthesis of amino- and amino-oxy-substituted 1,3,5-triazine arrays on polymeric membranes. J. Comb. Chem. 2000, 2, 361-369.
25. Scharn, D.; Germeroth, L.; Schneider-Mergener, J.; Wenschuh, H. Sequential Nucleophilic substitution on halogenated triazines, pyrimidines, and purines: A novel approach to cyclic peptidomimetics. J. Org. Chem. 2001, 66, 507-513.
26. Nichols, J. S.; Parks, D. J.; Consler, T. G.; Blanchard, S. G. Development of a scintillation proximity assay for peroxisome proliferator-activated receptor γ ligand binding domain. Anal. Biochem. 1998, 257, 112-119.
27. Mortensen, D. S.; Rodriguez, A. L.; Sun, J.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Furans with basic side chains: Synthesis and biological evaluation of a novel series of antagonists with selectivity for the estrogen receptor alpha. Bioorg. Med. Chem. Lett. 2001, 11, 2521-2524.
28. Henke, B. R.; Drewry, D. H.; Jones, S. A.; Stewart, E. L.; Weaver, S. L.; et al. 2-Amino-4,6-diarylpyridines as novel ligands for the estrogen receptor. Bioorg. Med. Chem. Lett. 2001, 11, 1939-1942.
29. Lesuisse, D.; Albert, E.; Bouchoux, F.; Cerede, E.; Lefrancois, J. M.; et al. Biphenyls as surrogates of the steroidal backbone. Part 1: Synthesis and estrogen receptor affinity of an original series of polysubstituted biphenyls. Bioorg. Med. Chem. Lett. 2001, 11, 1709-1712.
30. Endo, Y.; Iijima, T.; Yamakoshi, Y.; Fukasawa, H.; Miyaura, C.; et al. Potent estrogen agonists based on carborane as a hydrophobic skeletal structure: A new medicinal application of boron clusters. Chem. Biol. 2001, 8, 341-355.
31. Tedesco, R.; Youngman, M. K.; Wilson, S. R.; Katzenellenbogen, J. A. Synthesis and evaluation of hexahydrochrysene and tetrahydrobenzofluorene ligands for the estrogen receptor. Bioorg. Med. Chem. Lett. 2001, 11, 1281-1284.
32. Stauffer, S. R.; Huang, Y.; Coletta, C. J.; Tedesco, R.; Katzenellenbogen, J. A. Estrogen pyrazoles: Defining the pyrazole core structure and the orientation of substituents in the ligand binding pocket of the estrogen receptor. Bioorg. Med. Chem. 2001, 11, 141-150.
33. Miller, C. P.; Collini, M. D.; Tran, B. D.; Harris, H. A.; Kharode, Y. P.; et al. Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. J. Med. Chem. 2001, 44, 1654-1657.
34. Minutolo, F.; Bertini, S.; Papi, C.; Carlson, K. E.; Katzenellenbogen, J. A.; et al. Salicylaldoxime moiety as a phenolic "A-ring" substitute in estrogen receptor ligands. J. Med. Chem. 2001, 44, 4288-4291.
35. Nishiguchi, G. A.; Rodriguez, A. L.; Katzenellenbogen, J. A. Diaryl-dialkyl-substituted pyrazoles: Regioselective synthesis and binding affinity for the estrogen receptor. Bioorg. Med. Chem. Lett. 2002, 12, 947-950.
36. Sun, J.; Huang, Y. R.; Harrington, W. R.; Sheng, S.; Katzenellenbogen, J. A.; et al. Antagonists selective for estrogen receptor α. Endocrinology 2002, 143, 941-947.
37. Anstead, G. M.; Carlson, K. E.; Katzenellenbogen, J. A. The estradiol pharmacophore: Ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 1997, 62, 268-303.
38. Brzozowski, A. M.; Pike, A. C. W.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; et al. Molecular basis of agonism and antagonism in the estrogen receptor. Nature 1997, 389, 753-758.
39. Wurtz, J.-M.; Egner, U.; Heinrich, N.; Moras, D.; Mueller-Fahrnow, A. Three-dimensional models of estrogen receptor ligand binding domain complexes, based on related crystal structures and mutational and structure-activity relationship data. J. Med. Chem. 1998, 41, 1803-1814.
40. Pike, A. C. W.; Brzozowski, A. M.; Hubbard, R. E.; Bonn, T.; Thorsell, A.-G.; et al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 1999, 18, 4608-4618.
41. Egner, U.; Heinrich, N.; Ruff, M.; Gangloff, M.; Mueller-Fahrnow, A.; et al. Different ligands-different receptor conformations: Modeling of the hERα LBD in complex with agonists and antagonists. Med. Res. Rev. 2001, 21, 523-539.
42. Tanenbaum, D. M.; Wang, Y.; Williams, S. P.; Sigler, P. B. Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 5998-6003.
43. Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998, 95, 927-937.
44. Matthews, J.; Celius, T.; Halgren, R.; Zacharewski, T. Differential estrogen receptor binding of estrogenic substances: A species comparison. J. Steroid Biochem. Mol. Biol. 2000, 74, 223-234.
45. Sanderson, J. T.; Seinen, W.; Giesy, J. P.; Van den Berg, M. 2-Chloro-s-triazine herbicides induce aromatase (CYP19) activity in H295R human adrenocortical carcinoma cells: A novel mechanism for estrogenicity? Toxicol. Sci. 2000, 54, 121-127.
46. Sanderson, J. T.; Letcher, R. J.; Heneweer, M.; Giesy, J. P.; Van den Berg, M. Effects of chloro-s-triazine herbicides and metabolites on aromatase activity in various human cell lines and on vitellogenin production in male carp hepatocytes. Environ. Health Perspect. 2001, 109, 1027-1031.
47. Klinge, C. M. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 2001, 29, 2905-2919.
48. Foster, A. B.; Jarman, M.; Leung, O. T.; McCague, R.; Leclercq, G.; et al. Hydroxy derivatives of tamoxifen. J. Med. Chem. 1985, 28, 1491-1497.
49. Grese, T. A.; Cho, S.; Finley, D. R.; Godfrey, A. G.; Jones, C. D.; et al. Structure-activity relationships of selective estrogen receptor modulators: Modifications to the 2-arylbenzothiophene core of raloxifene. J. Med. Chem. 1997, 40, 146-167.
50. Lambert, M. H. Docking conformationally flexible molecules into protein binding sites. In Practical Application of Computer-Aided Drug Design; Charifson, P. S., Ed.; Marcel Dekker: New York, 1997; Chapter 8, pp 243-303.
51. Insight II is available from Accelrys, Inc., San Diego, CA 92121.
52. Pike, A. C. W.; Brzozowski, A. M.; Walton, J.; Hubbard, R. E.; Thorsell, A.-G.; et al. Structural insights into the mode of action of a pure antiestrogen. Structure 2001, 9, 145-153.
53. Shiau, A. K.; Barstad, D.; Radek, J. T.; Meyers, M. J.; Nettles, K. W.; et al. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat. Struct. Biol. 2002, 9, 359-364.